SEC Form 4 · accession 0001179110-18-001912
Tempest Therapeutics, Inc. · TPST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan Gillis
Officer — Senior Vice President, Finance
Period of report
Feb 8, 2018
Accepted (ET)
Feb 9, 2018 · 6:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001544227
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.93 | Feb 8, 2018 | A | 128,645 | A | — | Feb 8, 2028 | Common Stock | 128,645 | 128,645 | D |
Explanation of responses
- F1The option shall vest as to 25% of the shares on February 8, 2019 and the remaining shares shall vest in equal quarterly installments over 12 quarters, ending February 8, 2022.